EGFR and ovarian cancer: The therapeutic potential of FLRT3 blockade to enhance T cell–based immunotherapies in solid tumors was tested in zebrafish xenograft models of ovarian cancer (OVCAR-5) and RD together with EpCAM CAR-T cells or EGFR/CD3 BiTEs, respectively (Fig. 7, A and E).